Abstract
Itaconic acid, or methylenesuccinic acid, is not generally classified as a mammalian metabolite. Using NMR based metabolomics and 13C-labeling, we have detected itaconic acid in both macrophage-like VM-M3 and RAW 264.7 tumor cell lines as well as stimulated and unstimulated primary murine macrophages. Macrophage activation by addition of lipopolysaccharide and IFN-γ markedly increased itaconic acid production and secretion. Crude cell extracts synthesize itaconic acid via decarboxylation of cis-aconitate, indicative of a novel mammalian cis-aconitic decarboxylase activity. Our results highlight a previously unidentified biosynthetic pathway related to TCA cycle metabolism in mammalian cells and a novel metabolite that likely plays a role in macrophage-based immune response.
Keywords: metabolomics, NMR, LC-MS, itaconic acid, tumor cells, macrophages
Small molecule effectors of cells are often overlooked. A case in point is itaconic acid (methylenesuccinic acid) – a metabolite made and secreted by the fungal organism Aspergillus terreus.1, 2 The biosynthesis of this dicarboxylic acid has been of interest because it can be used as a starting material for chemical synthesis of polymers.3, 4 More recently, itaconic acid (ITA) has been identified in a small number of cases of metabolomic analysis of mammalian tissue specimens5–7. In those few cases, whether it was synthesized by mammalian cells or endogenous flora, or arose merely as an adventitious contaminant, was unknown. Despite the overall lack of study of ITA as a mammalian metabolite, there is evidence that ITA can be catabolized by both guinea pig and rat liver mitochondria.8,9
The VM-M3 murine tumor cell line is derived from a spontaneously arising brain tumor in a VM mouse.10 This cell line, reported to be metastatic, is similar in morphology to the well-characterized RAW 264.7 murine macrophage cell line, and both share properties of macrophages including gene expression and phagocytic capability.11, 12 We detected itaconic acid (ITA) in 1D-gHSQC NMR experiments (obtained on a Varian 600 MHz VNMRS equipped with a triple resonance probe) with methanol/water (80:20) extracts of VM-M3 cells that had been incubated with [13C5]glutamine or [13C6]glucose. [13C5]glutamine resulted in detection of proton resonances at 3.15 ppm characteristic of the ITA signal for the –13CH2– moiety; [13C6]glucose incubation gave rise to resonances consistent with labeled –13CH2– and =13CH2 (at 5.37 and 5.85 ppm) groups13. The 13C-labeled ITA was present at sufficiently high levels that it could easily be identified using 2D-gHSQC (Fig. 1A) and 2D-gHSQC-TOCSY experiments. The 1H resonances arising from itaconate were also confirmed by doping cell extracts with an itaconate standard. Using the size of the VM-M3 cells and cell count used for the extracts, and quantifying the amount of ITA in the extracts using MS methods, we estimate the intracellular concentration of this compound to be 1.33±0.16 mM.
13C-labeled ITA was also detected by 1D-gHSQC in an extract of the culture medium (Fig. 2) in which cells were incubated with [13C6]glucose for 12 h. In order to detect the ITA, the large amount of [13C6]glucose was removed from the resolubilized extract with Strata-X-A solid phase extraction cartridges (see Supporting Information for detailed treatment). Thus, this molecule appears to be secreted by the cells.
ITA may be a metabolite associated with a wide variety of tumors, or it could occur in a unique subset. We therefore investigated ITA synthesis in the macrophage-like RAW 264.7 cell line and the unrelated MCF-7 breast cancer cell line. Although 1H NMR has been used to profile the Raw 264.7 metabolome14, 15, the relatively low concentration of ITA would make it difficult to detect in the absence of 13C-labeling and selective analysis of protons coupled to 13C. gHSQC spectra of extracts from unstimulated RAW 264.7 cells incubated with [13C6]glucose exhibited a detectable amount of ITA (Fig. 1B), while extracts from the MCF-7 cell line incubated with the labeled glucose did not contain NMR-detectable levels of ITA. Moreover, analysis of several unrelated cell types (Escherichia coli strain NCM3722, Clostridium acetobutylicum strain ATCC 824, Saccharomyces cerevisiae strain CEN-PK, cultured human foreskin fibroblasts, or pancreatic tumor tissue) by LC-MS failed to reveal detectable levels of ITA. It is noteworthy that stimulation of RAW 264.7 cells with lipopolysaccharide (LPS) resulted in an increased level of detectable 13C-ITA (Fig. 1C); ITA was also detected in the tissue culture media of the RAW 264.7 cells as well as VM-M3 cells (Fig. 2). Thus, ITA synthesis is not a generic characteristic of all tumor cell lines, and might instead be indicative of those of macrophage lineage.
To test the possibility that ITA synthesis is a characteristic of macrophages, we analyzed unstimulated mouse peritoneal macrophages and activated macrophages following ex vivo stimulation with IFN-γ and LPS that were then incubated with [13C6]glucose. While very low levels of ITA could be detected in the unstimulated cell extracts (Fig. 1D), a dramatic increase was observed in the activated cells (Fig. 1E). This is consistent with the findings of Shin et al.5 who detected ITA in the lungs of mice infected with Mycobacterium tuberculosis, the primary site of inflammation and macrophage response to infection, but not other organs. As with the VM-M3 cells, ITA was also detected in the culture medium, but only in cells that had been stimulated with LPS. Therefore, production of ITA may represent a previously unrecognized facet of the macrophage-mediated immune response.
Multiple pathways have been proposed for the biosynthesis of ITA1, 16, 17 (Supplemental Information, Fig. S2). To distinguish among these, we used isotope tracers. The low concentration of ITA in the 13C-labeled extracts made direct 13C-detection by NMR impractical. Therefore, we used LC-MS measurements18 of ITA and its potential precursors including acetyl CoA, pyruvate, citrate and aconitate after incubating cells with [13C6]glucose or [13C5]glutamine (Fig. 3).
If the biosynthesis of ITA in mammalian cells occurs through the same pathway as in Aspergillus (decarboxylation of cis-aconitate followed by a 1,3-allylic rearrangement catalyzed by cis-aconitic decarboxylase, Fig. 4A)1, 19, 20, then incubation of the cells with [13C5]glutamine should yield [13C4]ITA as the primary isotopologue from the first turn of the TCA cycle. This results from glutamine hydrolysis to glutamate followed by transamination and production of α-ketoglutarate, which then enters the TCA cycle. This would ultimately result in [13C4]cis-aconitate that is site specifically decarboxylated to [13C4]ITA (Fig. 4B). [13C4]ITA is indeed the major isotopologue of itaconic acid present under these conditions (see Supplement Fig. S4). This pathway is further supported by the fact that we see vastly more 13C label at the –CH2- position than the =CH2 position by 1D-gHSQC NMR. Incubation of cells with [13C6]glucose, with the same biosynthetic scheme, should generate [13C1]ITA resulting from the [13C2]acetyl CoA that enters the TCA cycle and is converted to cis-aconitate, with one of the labeled carbons site-specifically lost during the cis-aconitate decarboxylase reaction (Fig. 4C). This 13C flux through pyruvate dehydrogenase (PDH) does indeed result in the major isotopologues observed by MS, although there is also appreciable flux through pyruvate carboxylase (PC).21, 22 PC generates [13C3]oxaloacetate that will ultimately result in the [13C4]ITA isotopologues (Fig. 4D). By comparing the percentage of total isotopologues of ITA resulting from PDH and PDH+PC flux ([13C1]and [13C4], respectively) to the percentage of total isotopologues of anticipated precursors citrate and aconitate from both PDH and PDH+PC fluxes ([13C2]and [13C5], respectively), we see that the three metabolites show comparable percentages from each flux. The isotope labeling data we have obtained (Fig. 4E) are thus fully consistent with a biosynthetic pathway in mammalian cells whereby ITA is synthesized via the specific decarboxylation of cis-aconitate from the TCA cycle. The NMR data, which shows significantly higher 13C labeling at the =CH2 resonance but still an appreciable amount of label at the –CH2- resonance in the 1D-gHSQC spectrum, further supports this pathway. This route requires the presence of a mammalian homologue of fungal cis-aconitic decarboxylase (cADC).23, 24 Other likely routes can be ruled out based on the labeling data (see Supporting Information).
The decarboxylation reaction catalyzed by cADC is unique amongst carboxy-lyases. cADC is the only carboxy-lyase in the ExPASy ENZYME database that catalyzes a decarboxylation resulting in both the reduction of a β-γ unsaturation as well as the formation of a methylidene group α to the decarboxylation. There are no identifiable mammalian sequence homologues of the Aspergillus cADC protein in the NCBI gene database and no structures of the fungal protein to suggest key motifs that could aid in identifying any structural homologues. Hence, we used crude cell extracts to assess in vitro synthesis of ITA. Because the RAW 264.7 cells generated a large amount of ITA when stimulated with LPS, we used cell extracts of these to assess in vitro synthesis of ITA. Crude RAW 264.7 cell lysates, prepared by Dounce homogenization in a hypotonic buffer, were incubated with 4 mM cis-aconitate for 3 h at 37°C. Metabolites were extracted, lyophilized, and examined by 1H NMR. There was a 40-fold increase in the intensity of the ITA 1H resonances compared to control extracts (Fig. 5), made either without the addition of cis-aconitate or using a boiled cell extract to inactivate any enzyme(s). VM-M3 lysates also generated significant amounts of ITA from cis-aconitate (Supplement Fig. S2). Thus, macrophage-derived cells possess a highly unusual enzymatic activity previously observed only in a few fungi.
Although ITA can be used to form synthetic polymers, that is unlikely to be its biological function. What is the purpose of the synthesis and excretion of this novel metabolite? ITA has been shown to be a potent inhibitor of isocitrate lyase25, 26, an enzyme of the glyoxylate cycle found in bacteria, so its secretion could be part of an antibacterial response. However, ITA has also been shown to inhibit phosphofructokinase27, and thus, could potentially be involved in regulation of metabolism. It is also possible that ITA acts as a signaling molecule involved in recruitment or regulation of other cells. That ITA levels in cells and culture supernatant significantly increase in response to IFN-γ and LPS points to a potential role in macrophage activation and/or macrophage effector responses. Macrophages are currently known to secrete over 100 substances of various molecular weights that are involved in inflammatory cell activation, proliferation, and effector cell migration.28 Interestingly, Raw 264.7 conditioned medium has been shown to induce migration and metastasis in colon cancer cells, due at least partially to secretion of chemokines.29 That the ITA metabolite was first noticed in a metastatic tumor cell line hints that it may also have a role in tumor biology. Observation of this novel metabolite opens up an array of future studies to determine its physiological function, including in the mammalian immune system and in cancer.
Supplementary Material
ACKNOWLEDGMENT
We thank Roberto Flores and Zeynep Akgoc, Biology Department, Boston College, for assistance with culturing the VM-M3 tumor cells. This work has been supported by the Department of Energy Office of Science, Energy Biosciences DE-FG02–91ER20025 (to M.F.R.) and NSF award CBET-0941143 and NIH Challenge Grant 1RC1 CA147961 (to J.D.R.).
Footnotes
Supporting Information. Details of VM-M3 and RAW 264.7 cell culture, murine peritoneal macrophage isolation, preparation of cell extracts, NMR and LC-MS methods are available as Supporting Information. This material is available free of charge via the Internet at http://pubs.acs.org.
REFERENCES
- 1.Bonnarme P, Gillet B, Sepulchre AM, Role C, Beloeil JC, Ducrocq C. J. Bacteriol. 1995;177:3573–3578. doi: 10.1128/jb.177.12.3573-3578.1995. 1995. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 2.Bentley R, Thiessen CP. Science. 1955;122:330. doi: 10.1126/science.122.3164.330. [DOI] [PubMed] [Google Scholar]
- 3.Yu C, Cao Y, Zou H, Xian M. Appl. Microbiol. Biotechnol. 2011;89:573–583. doi: 10.1007/s00253-010-2970-z. [DOI] [PubMed] [Google Scholar]
- 4.Okabe M, Lies D, Kanamasa S. Appl. Microbiol. Biotechnol. 2009;84:597–606. doi: 10.1007/s00253-009-2132-3. [DOI] [PubMed] [Google Scholar]
- 5.Shin J, Yang J, Jeon B, Yoon YJ, Cho S, Kang Y, Ryu DH, Hwang G. J. Proteome Res. 2011;10:2238–2247. doi: 10.1021/pr101054m. [DOI] [PubMed] [Google Scholar]
- 6.Kvitvang HFN, Andreassen T, Adam T, Villas-Boas SG, Bruheim P. Anal. Chem. 2011;83:2705–2711. doi: 10.1021/ac103245b. [DOI] [PubMed] [Google Scholar]
- 7.Wibom C, Surowiec I, Moren L, Bergstrom P, Johansson M, Antti H, Bergenheim AT. J. Proteome Res. 2010;9:2909–2919. doi: 10.1021/pr901088r. [DOI] [PubMed] [Google Scholar]
- 8.Adler J, Wang S, Lardy HA. J. Biol. Chem. 1957;229:865–879. [PubMed] [Google Scholar]
- 9.Wang S, Adler J, Lardy HA. J. Biol. Chem. 1961;236(1):26–30. [PubMed] [Google Scholar]
- 10.Huysenstruyt LC, Mukherjee P, Banerjee D, Shelton LM, Seyfried TN. Int. J. Cancer. 2008;123:73–84. doi: 10.1002/ijc.23492. [DOI] [PubMed] [Google Scholar]
- 11.Huysenstruyt LC, Shelton LM, Seyfried TN. Int. J. Cancer. 2010;126:65–72. doi: 10.1002/ijc.24649. [DOI] [PubMed] [Google Scholar]
- 12.Raschke WC, Baird S, Ralph P, Nakoinz I. Cell. 1978;15:261–267. doi: 10.1016/0092-8674(78)90101-0. [DOI] [PubMed] [Google Scholar]
- 13.Cui Q, Lewis IA, Hegeman AD, Anderson ME, Li J, Schulte CF, Westler WM, Eghbalnia HR, Sussman MR, Markley JL. Nature Biotech. 8. 2008;26:162–164. doi: 10.1038/nbt0208-162. [DOI] [PubMed] [Google Scholar]
- 14.Stuckey DJ, Anthony DC, Lowe JP, Miller J, Palm WM, Styles P, Perry VH, Blamire AM, Sibson NR. J. Leukocyte Biol. 2005;78:393–400. doi: 10.1189/jlb.1203604. [DOI] [PubMed] [Google Scholar]
- 15.Santini MT, Rainaldi G, Ferrante A, Romano R, Clemente S, Motta A, De Berardis B, Balduzzi M, Paoletti L, Indovina PL. Chem. Res. Toxicol. 2004;17:63–74. doi: 10.1021/tx034118f. [DOI] [PubMed] [Google Scholar]
- 16.Shimi IR, Nour El Dein MS. Arch. Microbiol. 1962;44:181–188. doi: 10.1007/BF00408905. [DOI] [PubMed] [Google Scholar]
- 17.Jakubowska J, Metodiewa D. Acta Microbiol. Pol. Ser. B Microbiol. Appl. 1974;6:51–61. [PubMed] [Google Scholar]
- 18.Lu W, Clasquin MF, Melamud E, Amador-Noguez D, Caudy AA, Rabinowitz JD. Anal. Chem. 2010;82:3212–3221. doi: 10.1021/ac902837x. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 19.Bentley R, Thiessen CP. J. Biol. Chem. 1957;226:703–720. [PubMed] [Google Scholar]
- 20.Ranzi BM, Ronchetti F, Russo G, Toma L. JCS Chem. Comm. 1981;785:1050–1051. [Google Scholar]
- 21.Merle M, Bouzier-Sore A-K, Canioni P. J. Neurochem. 2002;82:47–57. doi: 10.1046/j.1471-4159.2002.00924.x. [DOI] [PubMed] [Google Scholar]
- 22.Riazi R, Khairallah M, Cameron JM, Pencharz PB, Des Rosiers C, Robinson BH. Molec. Genetics Metab. 2009;98:349–355. doi: 10.1016/j.ymgme.2009.06.015. [DOI] [PubMed] [Google Scholar]
- 23.Dwiarti L, Yamane K, Yamatani H, Kahar P, Okabe M. J. Biosci. Bioeng. 2002;94:29–33. doi: 10.1263/jbb.94.29. [DOI] [PubMed] [Google Scholar]
- 24.Kanamasa S, Dwiarti L, Okabe M, Park EY. Appl. Microbiol. Biotechnol. 2008;80:223–229. doi: 10.1007/s00253-008-1523-1. [DOI] [PubMed] [Google Scholar]
- 25.McFadden BA, Purohit S. J. Bacteriol. 1977;131:136–144. doi: 10.1128/jb.131.1.136-144.1977. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 26.Williams JO, Roche TE, McFadden BA. Biochemistry. 1971;10:1384–1390. doi: 10.1021/bi00784a017. [DOI] [PubMed] [Google Scholar]
- 27.Sakai A, Kusumoto A, Kiso Y, Furuya E. Nutrition. 2004;20:997–1002. doi: 10.1016/j.nut.2004.08.007. [DOI] [PubMed] [Google Scholar]
- 28.Laskin DL, Pendino KJ. Annu. Rev. Pharmacol. Toxicol. 1995;35:655–677. doi: 10.1146/annurev.pa.35.040195.003255. [DOI] [PubMed] [Google Scholar]
- 29.Green CE, Liu T, Montel V, Hsiao G, Lester RD, Subramaniam S, Gonias LS, Klemke RL. PLoS ONE. 2008;4:e6713. doi: 10.1371/journal.pone.0006713. [DOI] [PMC free article] [PubMed] [Google Scholar]
Associated Data
This section collects any data citations, data availability statements, or supplementary materials included in this article.